Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13545740 | 0.82 | MAPK14 (0.46) | ALDH1A1MAPK14MEN1KMT2ARAB9A | |
| SCHEMBL13545723 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HPGDMEN1KMT2ARAB9A | |
| SCHEMBL2091654 | 0.82 | KDM1A (0.48) | ALDH1A1HPGDKMT2AADORA1 | |
| SCHEMBL2093695 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HPGDNISCHMEN1KMT2A | |
| SCHEMBL9955688 | 0.82 | NPSR1 (0.48) | ALDH1A1HPGDMAPK14NISCHMEN1 | |
| SCHEMBL30257384 | 0.82 | ALDH1A1 (0.54) | ALDH1A1MAPK14NISCHMEN1KMT2A | |
| SCHEMBL2093741 | 0.80 | ALDH1A1 (0.59) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7950236 | 0.80 | ALDH1A1 (0.64) | ALDH1A1HPGDMAPK14NISCHRAB9A | |
| SCHEMBL7946606 | 0.78 | ALDH1A1 (0.49) | ALDH1A1HPGDMEN1KMT2AXDH | |
| SCHEMBL31070149 | 0.78 | ENPP1 (0.44) | ALDH1A1MAPK14NISCHMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012085857-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085852-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20100022542-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | SHIONOGI & CO., LTD. | 2010-01-28 | — | — | US | disclosed |
| WO-2008087611-A2 | PYRROLIDINE- AND PIPERIDINE- BIS-AMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022542-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM | THPO, MPL, TEK | ALDH1A1 1545/4885HPGD 2102/4885MAPK14 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.